Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 (iptacopan) in active ANCA-associated vasculitis
CTR20242414Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iptacopan in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by Novartis. Started Aug 2024; status: active.
02
Drugs
Iptacopan
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on CTR20242414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242414.